Vanquish Minimally Invasive Prostate Cancer Therapy Achieves U.S. FDA Breakthrough Device Designation with Francis Medical

Francis Medical, Inc., a privately held medical device company, is celebrating a major milestone – the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its groundbreaking Vanquish water vapor ablation therapy, a minimally invasive treatment for prostate, kidney and bladder cancer. This revolutionary solution has the potential to revolutionize cancer treatment for those affected.

The Breakthrough Device Designation program is a revolutionary approach to improving healthcare for patients with life-threatening or irreversibly debilitating diseases or conditions. Through expediting the development, assessment, and review of innovative medical device technologies that have the potential to provide more effective treatment than current standards of care, patients can get access to the treatment they need faster and more conveniently. By helping bridge the gap between innovation and implementation of new medical device technologies, Breakthrough Device Designation is making a positive impact on improving patient care.

Prostate cancer is the second most common cancer in U.S. men, estimated to affect one in eight American men during their lifetime. But new advances in treatment, thanks to Francis Medical’s Vanquish water vapor technology, are making it possible for men battling this disease to find relief with fewer potential life-altering side effects. With this revolutionary technology, a few drops of sterile water are used to apply thermal energy directly to cancerous tissue, precisely ablate the cells while simultaneously protecting the surrounding structures. This simple transurethral procedure offers a safe, effective alternative to traditional cancer treatments.

Francis Medical is striving to revolutionize the way prostate cancer is treated, with the FDA recently recognizing its potential to become the first-line therapy of choice. Our cutting-edge technology promises to provide patients with a new approach which may reduce the adverse impacts of traditional treatments, allowing them to effectively and safely address their cancer. With an experienced team at the helm, we are committed to providing the best possible outcomes and experience for patients facing this difficult condition.

The long-awaited VAPOR 2 pivotal study has begun! Initiated by the company in order to gain U.S. market clearance, the study will treat 235 patients with localized, intermediate-risk prostate cancer at up to 30 centers across the country. This revolutionary study could be the key to providing these patients with an effective and life-saving treatment option.

About Francis Medical:

Francis Medical is dedicated to revolutionizing the way prostate cancer is treated, allowing patients to fight cancer without sacrificing life-altering side effects. Drawing inspiration from the inventor’s late father, Francis Hoey, who experienced cruel treatments for his prostate cancer before succumbing to the disease in 1991, the company uses Sterile Water Vapor technology to target cancerous tissue simply and effectively. This cutting-edge approach seeks to minimize incontinence and erectile dysfunction side effects, allowing cancer patients to preserve their quality of life. To learn more, visit or call (763) 951-0370.

Leave a Comment